Retrospective Evaluation of the Pancreatic Cancer Patients Who Received Chemoradiotherapy


KARACA F. , Afsar C. U. , OKTEM O., ALMALI N., Yilmazer G., Keskin S., et al.

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, cilt.6, ss.327-332, 2015 (ESCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 6
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4328/jcam.2975
  • Dergi Adı: JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE
  • Sayfa Sayısı: ss.327-332

Özet

Aim: Pancreatic cancer is a highly lethal malignancy and in locally advanced disease, chemotherapy (CT) or chemoradiotherapy (CRT) are implemented. The aim of this retrospective study was to investigate the general characteristics and survival of our patients receiving CRT. Material and Method: Between the years 2009-2013, 62 pancreatic cancer patients were taken into study who admitted to Van Training and Research Hospital. Eight patients who had whipple operation received radiotherapy (RT) with concurrent CT. Fifty-four patients who were considered to be inoperable underwent CRT. As adjuvant treatment dose, 45 Cy (1,8 Gy/fx/day) radiotherapy was administered to pancreas and regional lymph nodes. In patients who had taken definitive CRT, average 50.4 Cy (1.8 Gy/fx/day) dose was given. Statistical analysis was carried out using SPSS 19 software package; Kaplan-Meier analysis method was used for survival and log-range test for comparisons. Results: Twenty-four patients (38.7%) were female and 38 (61.3%) were wale. Eleven patients (1 7.7%) were at stage IA, 15 (25.8%) were stageI9,13 (20.9%) were stage HA, 8 (12.9%) were stage IIB and 14 (22.5%) were staged as stage HI. Two-year disease free survival (DES): time from the date of biopsy until the date of recurrence was approximately 436 days and the median DFS was found to be 362 days. The average overall survival (OS) time; time from the date of biopsy until the date of death were found to be approximately 854 days, the median survival time was found to be 916 days. Survival due to tumor localization (head, body and tail) showed no significant difference statistically (log-range chi-square=0.366;p=0.833). Discussion: According to our single center experience, our data in pancreatic cancer patients were parallel with international data. In preclinical experiments, effective drug therapies for curative modalities are under investigation for pancreatic cancer patients.